Product Description
a treatment for diabetic gastroparesis
Mechanisms of Action: nAChR Modulator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Catalyst Biosciences
Company Location: Eastern America
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Gastroparesis|Constipation|Irritable Bowel Syndrome
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02187094 |
TC-6499-12-CLP-005 | P2 |
Completed |
Gastroparesis |
2015-01-01 |
2019-03-20 |
Treatments |
|
2010-018902-35 |
QCL-105018 (TC-6499-12-CLP-004) | P2 |
Completed |
Constipation|Irritable Bowel Syndrome |
2010-11-02 |
2022-03-13 |
Treatments |
|
NCT01149200 |
TC-6499-12-CLP-004 | P2 |
Completed |
Constipation|Irritable Bowel Syndrome |
2010-10-01 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|